Archon emerges from stealth with $20M and ‘antibody cages’ to power up drug development

Archon Biosciences, a biotech startup putting AI to work designing novel biomolecules, has just emerged from stealth with an impressive $20 million in seed funding. The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. This is the first company to be […]

© 2024 TechCrunch. All rights reserved. For personal use only.

Archon Biosciences, a biotech startup putting AI to work designing novel biomolecules, has just emerged from stealth with an impressive $20 million in seed funding. The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. This is the first company to be
© 2024 TechCrunch. All rights reserved. For personal use only.[#item_full_content]